Skip to main content

Rising Prevalence of Hereditary Diseases to Augment the Cardiac Biomarkers Market

Home » Press Release » Rising Prevalence of Hereditary Diseases to Augment the Cardiac Biomarkers Market

May 24, 2022

Rising Prevalence of Hereditary Diseases to Augment the Cardiac Biomarkers Market

The global cardiac biomarkers market is anticipated to exhibit a growth of a CAGR of 11.3% between 2019 to 2027.

There are quite a few factors that drive the cardiac biomarkers market such as the rising prevalence of hereditary diseases, the increasing elderly population, etc.

ResearchMoz elucidates the detailed insights on the market including market size, challenges, threats, opportunities, etc.

Detection of Myocardial Infarction to Drive Cardiac Biomarkers Market

The rising incidences of myocardial infarction is expected to drive the cardiac biomarkers market. Biomarkers such as Troponin can detect acute myocardial infarction. Creatine Kinase MB and Troponin both can detect early-stage acute myocardial infarction, leading to the growth of the global cardiac biomarkers market.

Acute Coronary Syndrome Segment to Boost the Demand

Acute Coronary Syndrome will increase the growth opportunities manifold in the cardiac biomarkers market in the coming years. U.S alone registers, nearly 780,000 cases of Acute Coronary Syndrome are registered each year, paving the way for the cardiac biomarkers to grow in the coming years.

The high cost of testing is expected to hinder market growth in the coming years.

Nevertheless, the high prevalence of cardiovascular diseases (CVDs) will add to growth opportunities in the global cardiac biomarkers market over the forecast years.

Analysts Views

Biomarkers that help in the diagnosis of cardiac diseases and provide information about their effectiveness have a lot to offer. Different types of biomarkers can diagnose different heart conditions, which is helpful. In clinical practice, most commonly used markers are high-sensitivity cardiac troponin, N-terminal pro B type natriuretic peptide and myoglobin but there is always room for better ones as well alongside nanotechnologies to improve our diagnostic techniques.

Early markers identified by enzymes sometimes also serve as diagnostics helping with growth opportunities globally.

These biomarkers have been simplified over time with nanotechnologies like electrochemiluminescence (ECL) and electrode chemistry, thus driving growth for this market.

Regional Overview

The Asia Pacific region is projected to hold a lion’s share in the cardiac biomarkers market during the forecast period, owing to the growing prevalence of lifestyle-related disorders in this region. China is dominating the Asia Pacific market, followed by Japan due to increasing cases of cardiovascular diseases.

Competitive Landscape

ResearchMoz shares a detailed report on the competitive landscape of this market which would allow the new entrants to make informed decisions to thrive in this space.

One of the key strategies companies use in the cardiac biomarkers market is the acquisition of companies offering complementary products or services. This allows them to capture other regional markets with their product offerings and cater better to their customers.

The players in the market are –

  • Thermo Fisher Scientific Inc.
  • bioMérieux SA
  • Hoffmann-La Roche AG
  • Abbott
  • Siemens AG
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Creative Diagnostics

Key Takeaways

Some of the key takeaways from the comprehensive report available with ResearchMoz include-

  • The cardiac biomarkers will exhibit a growth rate of 11.3% from 2019 to 2027.
  • Nanotechnologies have been applied to electrochemiluminescence (ECL) due to their excellent biocompatibility as well as electrical properties, driving the global market over the next few years.
  • During the Covid-19 pandemic, early enzyme markers were used as well due to their cost-effective nature, resulting in increased market demand globally over time.
  • The most commonly used biomarker is high-sensitivity cardiac troponin, N-terminal pro B–type natriuretic peptide, and Myoglobin, resulting in the growth opportunities of the cardiac biomarkers market.
  • Asia Pacific region will grow remarkably well during the forecast period owing to growing prevalence of cardiovascular diseases.

By Indication

Myocardial Infarction

  • Congestive Heart Failure
  • Acute Coronary Syndrome

By Biomarker

  • Troponin
  • Creatine Kinase-MB (CK-MB)
  • Myoglobin
  • B-type Natriuretic Peptide (BNP)

By End User

  • Specialty Clinics
  • Hospitals

Regional Outlook

North America

  • U.S.
  • Canada


  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Greece
  • The Netherlands

Asia Pacific

  • Japan
  • China
  • India

Latin America

  • Mexico
  • Brazil
  • Argentina

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

Media Contact

Please drop a mail to the Global PR Team for your queries

Contact Us

We Are Just A Click Away!

[email protected]